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We conducted a prospective multicenter study in Spain to characterize the mechanisms of resistance to amoxicillin-clavu-
lanate (AMC) in Escherichia coli. Up to 44 AMC-resistant E. coli isolates (MIC > 32/16 g/ml) were collected at each of the
seven participant hospitals. Resistance mechanisms were characterized by PCR and sequencing. Molecular epidemiology
was studied by pulsed-field gel electrophoresis (PFGE) and by multilocus sequence typing. Overall AMC resistance was
9.3%. The resistance mechanisms detected in the 257 AMC-resistant isolates were OXA-1 production (26.1%), hyperpro-
duction of penicillinase (22.6%), production of plasmidic AmpC (19.5%), hyperproduction of chromosomic AmpC
(18.3%), and production of inhibitor-resistant TEM (IRT) (17.5%). The IRTs identified were TEM-40 (33.3%), TEM-30
(28.9%), TEM-33 (11.1%), TEM-32 (4.4%), TEM-34 (4.4%), TEM-35 (2.2%), TEM-54 (2.2%), TEM-76 (2.2%), TEM-79
(2.2%), and the new TEM-185 (8.8%). By PFGE, a high degree of genetic diversity was observed although two well-defined
clusters were detected in the OXA-1-producing isolates: the C1 cluster consisting of 19 phylogroup A/sequence type 88
[ST88] isolates and the C2 cluster consisting of 19 phylogroup B2/ST131 isolates (16 of them producing CTX-M-15). Each
of the clusters was detected in six different hospitals. In total, 21.8% of the isolates were serotype O25b/phylogroup B2
(O25b/B2). AMC resistance in E. coli is widespread in Spain at the hospital and community levels. A high prevalence of
OXA-1 was found. Although resistant isolates were genetically diverse, clonality was linked to OXA-1-producing isolates of
the STs 88 and 131. Dissemination of IRTs was frequent, and the epidemic O25b/B2/ST131 clone carried many different
mechanisms of AMC resistance.
Escherichia coli is an important etiologic agent for both nosoco-mial- and community-acquired infections in humans (9, 13,
22). Amoxicillin-clavulanate (AMC) is one of the most widely
used antibiotics in many countries (3, 11, 15). In Spain, a 34.7%
increase in community use of AMC was recorded from 2000 to
2006 (20). Recently, blood isolates of E. coli nonsusceptible to
AMC increased from 9.3% (2003) to 25.9% (2010) in Spain,
according to the European Antimicrobial Resistance Surveil-
lance Network (EARS-Net [http://ecdc.europa.eu/en/activities
/surveillance/EARS-Net/database/Pages/database.aspx]) (20).
Enzymatic mechanisms of E. coli resistance to AMC include
hyperproduction of plasmid-mediated class A -lactamases such
as TEM-1 and SHV-1 (18, 31), plasmid-mediated AmpC-type
-lactamase (p-AmpC) (21), chromosomal AmpC -lactamase
(c-AmpC) (21), production of inhibitor-resistant TEM (IRT)
-lactamases (17, 27), plasmid-mediated -lactamase OXA-1
(32), and complex mutant TEM (CMT) enzymes than combine
IRT- and extended-spectrum -lactamase (ESBL)-type substitu-
tions (26).
In spite of the significant increase in AMCuse in the last several
years, there is little recent information available about the preva-
lence of AMC resistance mechanisms in E. coli; most previous
studies analyzed strains isolated more than 10 years ago from sin-
gle hospitals in the United States (12, 28), France (16), and Spain
(19, 24).
Accordingly, the aim of this prospective Spanish national mul-
ticenter study was to investigate the epidemiology and mecha-
nisms of AMC resistance in clinical isolates of E. coli causing both
community and nosocomial infections.
MATERIALS AND METHODS
Study design and bacterial isolates. A prospective multicenter study was
designed to obtain E. coli isolates resistant to AMC (MIC of  32/16
g/ml and/or disk inhibition zone of 13 mm according to the Clinical
and Laboratory Standards Institute [CLSI]) (7) from clinical samples col-
lected between January 2010 and May 2010. Seven university hospitals of
six Spanish Autonomous Communities andmembers of the SpanishNet-
work for Research in Infectious Diseases (REIPI) participated. Investiga-
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tors at these hospitals were asked to collect up to 22 consecutive commu-
nity- and 22 nosocomial-acquired, nonduplicated isolates of E. coli
resistant to AMC.
Nosocomial-acquired isolates were defined as those acquired at least
48 h after hospital admission. Putative community-acquired isolates were
those isolated in the community or within 48 h of hospital admission.
Susceptibility testing. The disk diffusion and/or microdilution sus-
ceptibility tests were performed using different automated systems in each
participating laboratory. All isolates were submitted to the antibiotic lab-
oratory of the Centro Nacional deMicrobiología (Majadahonda,Madrid,
Spain), where additional confirmatory antibiotic susceptibility testingwas
performed with the agar dilution method according to the CLSI guide-
lines (6). Control strains used were E. coli ATCC 25922 and E. coli ATCC
35218. The production of extended-spectrum -lactamases (ESBLs) was
studied by the double-disc synergy test and/or Etest ESBL using cefo-
taxime and ceftazidime as substrates (AB Biodisk, Solna, Sweden).
Molecular characterization of mechanisms of resistance to AMC.
The blaTEM gene and its promoter region were assessed by PCR and se-
quencing (10). Sequences were compared to those of the blaTEM-1 gene
and its promoter region in public databases (GenBank accession number
AB194682) (29). For isolates in which the promoter region could not be
amplified with these primers, the possibility of linkage of blaTEM alleles to
IS26-like elements, as suggested previously (1), was assessed with primers
IS26-F (5=-GCGGTAAATCGTGGAGTGAT-3=) and TEMi-R (5=-TCT
TTT ACT TTC ACC AGC GTT-3=).
Genes coding for p-AmpC -lactamases (CIT, DHA, ACC, EBC,
MOX, and FOX) and blaOXA-1 were characterized by PCR amplification
with specific primers and sequencing (2, 23, 25) in all isolates. E. coli
isolates that had negative results for p-AmpC -lactamases but that dis-
played a resistance phenotype consistent with AmpC production on the
basis of their resistance to AMC and cefoxitin and inhibition with phenyl
boronic acid and cloxacillin (cefotetan/cefotetan-cloxacillin Etest; AB
bioMérieux, Solna, Sweden) were categorized as c-AmpC.
Isolates carrying only the blaTEM-1 or blaSHV-1 genes with resistance to
ampicillin, AMC, and cefazolin but susceptibility to the remaining -lac-
tam antibiotic families were considered penicillinase hyperproducers. In
the case of SHV-1, an increase in the ceftazidimeMICwas also considered
compatible with hyperproduction of this enzyme (18).
Genes coding ESBL enzymes (CTX-M, SHV-type, and TEM-type)
were studied by PCR and sequencing in all AMC-resistant E. coli isolates
with phenotypes consistent with ESBL production on the basis of their
resistance to the extended-spectrum cephalosporins whose activity was
recovered in the presence of clavulanate (23).
Phylogenetic groups and detection of the O25b type. The phyloge-
netic groups of AMC-resistant E. coli isolates were determined by a mul-
tiplex PCR assay described by Clermont et al. (4). To search for an ST131/
B2/O25b E. coli clone, the detection of the O25b type was performed with
an allele-specific PCR (5).
Molecular epidemiology.The genetic relationship between theAMC-
resistant E. coli isolates was determined by pulsed-field gel electrophoresis
(PFGE) after total chromosomal DNA digestion with XbaI (23).
A selected sample of 43 AMC-resistant E. coli isolates, representing the
two major PFGE clusters (19 isolates each) and 5 IRT-producing isolates
belonging to serotype O25b phylogroup B2 isolates, was studied further
by multilocus sequence typing (MLST), according to the University Col-
lege Cork (Éire) scheme for E. coli (http://mlst.ucc.ie/mlst/dbs/Ecoli; data
last accessed on 20 July 2011).
Statistical analyses. Differences in the prevalence of mechanisms of
resistance and phylogroups between different groups were assessed by
Fisher’s exact test. Association was determined by calculation of the odds
ratio (OR) with 95% confidence intervals (CIs). The null hypothesis was
rejected for values of P of0.05. Statistical analyses were performed using
GraphPad Prism, version 3.02, software (GraphPad Software, Inc., San
Diego, CA).
RESULTS AND DISCUSSION
Bacterial isolates andmechanisms of AMC resistance.A total of
257 clinical AMC-resistant E. coli isolates were collected; 110 of
them (43%) produced nosocomial-acquired infections, and 147
(57%) putatively produced community-acquired infections; 170
of the isolates (65.9%) were from urine, 30 (12%) were from
wound, 19 (7.4%) were from blood, and 38 (14.7%) were from
other clinical samples.
During the study period, the participant hospitals had a prev-
alence of AMC resistance in E. coli (MIC 32/16 g/ml) of 9.3%
(range, 3.3% to 13.5%).
The mechanisms of resistance detected were production of
OXA-1 (67 isolates, or 26.1%), hyperproduction of penicillinase
(58 isolates, or 22.6%; 53 TEM-1 and 5 SHV-1), production of
p-AmpC (50 isolates, or 19.5%), hyperproduction of c-AmpC (47
isolates, or 18.3%), and production of IRTs (45 isolates, or
17.5%). In one AMC-resistant isolate with the ESBL phenotype,
blaTEM-12 was detected linked to an IS26 element upstream of
blaTEM. In two isolates, no enzymatic mechanism of resistance to
AMC was identified. Two different mechanisms of AMC resis-
tance were present in 13 isolates: OXA-1 with p-AmpC (7 isolates,
or 2.7%) and OXA-1 with c-AmpC (6 isolates, or 2.3%).
The IRTs identified in this study were TEM-40 (15 isolates, or
33.3%), TEM-30 (13 isolates, or 28.9%), TEM-33 (5 isolates, or
11.1%), TEM-32 (2 isolates, or 4.4%), TEM-34 (2 isolates,
or 4.4%), TEM-35 (1 isolate, or 2.2%), TEM-54 (1 isolate, or
2.2%), TEM-76 (1 isolate, or 2.2%), TEM-79 (1 isolate, or 2.2%),
and the new TEM-185 (4 isolates, or 8.8%), first described in this
study.
Of the 50 p-AmpC -lactamases detected in our study, 37
(74%) were CMY-2, 11 (22%) were DHA-1, 1 (2%) was CMY-30,
and 1 (2%) was CMY-42.
There were some relevant geographical differences in the prev-
alence of the AMC resistance mechanisms. For instance, the p-
AmpC mechanism was more prevalent in the isolates from the
Sant Pau Hospital, Catalonia, Spain (45.7%; P 0.0001) than in
isolates from the other hospitals; c-AmpCwas alsomore prevalent
in isolates from the Vall d’Hebron Hospital, Catalonia, Spain
(37.5%; P  0.022); OXA-1 was more prevalent in isolates from
the Complejo Hospitalario A Coruña, Galicia, Spain (46.5%; P
0.0019); IRT was more prevalent in isolates from the Gregorio
Marañón Hospital, Madrid, Spain (30%; P 0.038).
Previous studies detected the hyperproduction of penicilli-
nases (12, 24, 28), mainly TEM-1, and AmpC production (16, 19)
as the most common mechanisms of resistance to AMC in E. coli.
A 2011 study showed that of 50 ampicillin-sulbactam-resistant E.
coli isolates from the United States, 96% produced blaTEM-1, 8%
produced blaCMY-2, and 8% produced blaOXA-1 (31).
Some information about p-AmpC production in AMC-resis-
tant E. coli has been published previously (16, 19, 24, 28); one
study from the United States reported that of 69 E. coli isolates
resistant to AMC, 5.8% produced CIT (12).
Production of OXA-1 in E. coli has been sporadically described
previously (12, 16, 19, 24). The highest-reported OXA-1 preva-
lence (15.3%) was observed in isolates from the United States
collected between 1990 and 1994 (28); by the end of the last cen-
tury, this figure was 7.6% (24) and 2.6% (19) in two Spanish
hospitals.
The prevalence of IRTs found in this study is among the highest
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reported in AMC-resistant E. coli isolates (12, 19, 24, 28). How-
ever, of 255 E. coli isolates resistant to AMC studied in France in
1996 to 1998, 37.7% produced IRTs (16). Recently, in a single
Spanish hospital (17) 11.8% of AMC-resistant E. coli isolates pro-
duced IRTs.
Overexpression of blaTEM-1 has been associated with promot-
ers PaPb, P4, and others (10, 14, 30), but in this study this associ-
ation was not clearly observed since 50.9% of our TEM-1 produc-
ers had the most commonly found P3 promoter (Table 1).
However, our findings are consistent with a previous report of a
54.5% prevalence of P3/TEM-1 among ampicillin-sulbactam-re-
sistant E. coli isolates (31). In our study, the most prevalent strong
promoter was PaPb, as previously described (31) (Table 1).
Among our IRTs, 62.2% had promoters other than P3, most of
which were PaPb (Table 1). The implications of the promoter
variations in AMC resistance require further elucidation. The oc-
currence of IS26 located at different positions upstream of the
blaTEM gene has been recently described (1), but the influence of
this insertion in the expression of the blaTEM is unclear so far.
A total of 37 isolates (14.4%) produced ESBLs: 28 (75.7%)
produced CTX-M-15, 7 (18.9%) produced CTX-M-14, 1 (2.7%)
produced SHV-12, and 1 (2.7%)producedTEM-12. All but one of
them had an additional AMC resistance mechanism, mainly
OXA-1 (67.6%), p-AmpC (13.5%), c-AmpC (13.51%), and IRTs
(5.4%). Complex mutant TEM -lactamases were not detected.
In relation to the AMC resistance mechanisms, no significant
differences were found between community and nosocomial iso-
lates except for blaTEM-1 promoters other than P3, which were
more frequent in nosocomial AMC-resistant E. coli (P 0.05).
Table 2 shows the distribution of MIC50s and MIC90s, MIC
ranges, and the percentages of isolates with MICs of 32/16
g/ml according to the molecular mechanisms of resistance to
AMC. OXA-1-producing isolates had AMCMICs lower than iso-
lates with other AMC resistance mechanisms (P  0.03). Resis-
tance to non--lactam antibiotics in relation to themechanism of
AMC resistance is detailed in Table 3. OXA-1-producing isolates
were more resistant to ciprofloxacin, cotrimoxazole, and amino-
glycosides than IRT, AmpC, or TEM-1 producers (P 0.001).
Phylogenetic groups and detection of the O25b type. Of the
257 AMC-resistant E. coli isolates, 76 (29.6%) belonged to phylo-
genetic group A, 32 (12.4%) belonged to group B1, 104 (40.5%)
belonged to group B2, and 45 (17.5%) belonged to group D.
Phylogroup A was more frequent in OXA-1 producers (36, or
53.7%; P 0.0003); phylogroup B2 was more frequent in IRT pro-
ducers (24,or53.3%;P0.06), p-AmpCproducers (21,or42%;P
0.87), and TEM-1 producers carrying promoters other than P3 (16,
or 61.6%;P0.03); andphylogroupDwasmore frequent inTEM-1
producers with P3 promoters (13, or 48.1%; P 0.0001).
Of the 104 phylogroup B2 isolates, 56 (21.8% of all isolates)
were serotype O25b, which was detected in all seven participant
hospitals. Of the O25b/B2 isolates, 22 (39.3%) were OXA-1 pro-
ducers, 15 (26.8%)were TEM-1 producers with different promot-
ers, 11 (19.6%)were p-AmpCproducers, 8 (14.3%)were c-AmpC
producers, and 5 (8.9%)were IRT producers. Five of these isolates
produced both OXA-1 and AmpC -lactamases.
Molecular epidemiology. Ahigh degree of genetic diversity was
observed according to PFGE as 235 different PFGE patterns were
obtained from the 257 AMC-resistant E. coli isolates analyzed. How-
ever, twowell-definedclustersweredetected: clusterC1(genetic link-
age of90%) consisting of 19 OXA-1-producing isolates of phylo-
groupA, detected in six of the seven participant hospitals, and cluster
C2 (genetic linkageof80%)consistingof 19AMC-resistant isolates
of phylogroup B2 and serotype O25b, detected in six of the seven
participant hospitals. Of these 19 C2 isolates, 12 produced OXA-1
and CTX-M-15, 3 produced OXA-1 only, 3 produced CTX-M-15
and c-AmpC, and 1 produced CTX-M-15 andDHA. Figure 1 shows
the PFGE profiles of the 67 OXA-1-producing isolates.
TABLE 1 The frequency of promoter regions and insertions and
deletions identified in TEM-producing E. coli isolates
TEM type (n)a
Promoter class (no. of
isolates) No. of isolates with:
P3 PaPb P4 Pdel
IS26
insertionb
IS911
insertionc
C31¡T39
deletion
TEM-1 (53) 27 18 2 4 1 1
TEM-40 (15) 6 6 3
TEM-30 (13) 5 6 1 1
TEM-33 (5) 2 3
TEM-185 (4) 3 1
TEM-32 (2) 2
TEM- 34 (2) 2
TEM-35 (1) 1
TEM-76 (1) 1
TEM-79 (1) 1
a n, number of isolates.
b The IS26 element was detected upstream of blaTEM, inserted at promoter position 150
(n 3) or 46 (n 2) according to the Sutcliffe numbering system (29).
c The IS911 element was detected upstream of blaTEM-1, inserted at promoter
position 46.
TABLE 2 MIC values and ranges by resistance mechanism of AMC-
resistant E. coli isolates
Resistance
mechanism (n)a
MIC50
(g/ml)
MIC90
(g/ml)
MIC range
(g/ml)
% of isolates
with a MIC
 32/16
g/ml
OXA-1 (54) 32/16 64/32 16/8–128/64 40.3
IRT (45) 64/32 128/64 16/8–128/64 93.3
p-AmpC (43) 64/32 128/64 32/16–128/64 92
c-AmpC (41) 64/32 128/64 32/16–128/64 83
P3/TEM-1 (27) 64/32 64/32 16/8–128/64 66.7
Pdf3/TEM-1 (26)b 64/32 128/64 16/8–128/64 84.6
OXA-1AmpC (13) 64/32 64/32 32/16–64/32 53.8
a n, number of isolates.
b Isolates with blaTEM-1 and with promoters other than P3.
TABLE 3 Resistance to non--lactam antibiotics in relation to the
mechanism of resistance to AMC in E. coli
Resistance
mechanism
or source
(n)a
No. of isolates (%) with resistance to:
Ciprofloxacin Gentamicin Tobramycin Amikacin Cotrimoxazole
TEM-1 (53) 27 (51.8) 7 (13.2) 10 (20.4) 0 30 (56.6)
IRTs (45) 17 (37.8) 4 (8.9) 4 (8.9) 0 24 (53.3)
OXA-1 (67) 57 (85.1) 34 (50.7) 55 (82.1) 12 (17.9) 55 (82.1)
AmpC (97) 51 (52.6) 17 (17.5) 23 (23.7) 1 (1) 44 (45.4)
Total (257) 149 (58) 61 (23.7) 86 (33.5) 12 (4.7) 149 (58)
a n, number of isolates.
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FIG 1 Dendrogram illustrating the percent linkage of PFGE profiles of 67 OXA-1-producing E. coli isolates resistant to AMC. Isolate numbers are shown to the
right of the dendrogram.
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ByMLST, the PFGE C1 cluster was identified as ST88, and the
PFGE C2 cluster was identified as ST131.
Dissemination of OXA-1 -lactamase in AMC-resistant E. coli
isolates in Spain is due in part to the clonal spread of the epidemic
ST131 clone producing CTX-M-15 and OXA-1 and to the spread
of the ST88 phylogroup A clone producing only OXA-1, an asso-
ciation first described here. ST88 has been previously described in
association with c-AmpC production in a French hospital (8). On
the website of the University College of Cork (Ireland), 23 ST88 E.
coli isolates are registered that were recovered from infections of
humans and domestic animals (http://mlst.ucc.ie/mlst/dbs/Ecoli;
data last accessed on 20 July 2011).
In 24 O25b/B2 isolates, including 19 C2 isolates and 5 isolates
producing IRTs,MLSTwas performed, and results showed that all of
themwere ST131.We found thatO25b/B2/ST131E. coli isolates car-
ried not onlyCTX-M-15 andOXA-1 enzymes as previously reported
but also TEM-30, TEM-34, TEM-40, and TEM-54 IRT enzymes. To
the best of our knowledge, this is the first description of IRT-produc-
ing isolates belonging to the ST131 international clone.
TEM-185 characterization.The new IRTTEM-185 has a dou-
ble amino acid substitution at positions 69 (M¡L) and 165
(W¡L) in comparison with TEM-1 (GenBank accession number
1446016); these positions are frequentlymodified in IRT enzymes.
TEM-185 is similar to TEM-39 except that the latter has an addi-
tional substitution at position 276 (N¡D) (http://www.lahey.org
/studies/temtable.asp; data last accessed on 2 August 2011).
TEM-185was detected in four E. coli isolates belonging to phy-
logroup A; they were isolated in two geographically distant Span-
ish hospitals with two isolates each. Two of them were closely
related (genetic similarity of85% and same P4 promoter), and
the two additional isolates were genetically unrelated and had two
different promoters, P4 and Pdel. These findings suggest that sev-
eral clones can spread TEM-185.
Concluding remarks. Our findings suggest a complex epide-
miological background in which E. coli acquires AMC resistance
by several mechanisms, including clonal (ST131 and ST88) and
nonclonal spread, dissemination of mobile genetic elements car-
rying different bla genes, and eventual mutations in individual
isolates as a response to selective antimicrobial pressure.
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